Our liquid (serum/plasma samples) TKa-biomarker assay measures thymidine kinase activity (TKa) which reflects tumor cell proliferation. The biomarker assay is used by pharma in the following ways:
- TKa as a very potent biomarker in providing dose-response information and in use for dose optimization (Minimal Effective Dose Finding; FDA Project Optimus).
- TKa for upfront selection of patients for a specific treatment.
- TKa for early on-treatment monitoring and selection of patients for a specific treatment.
- TKa for on-treatment monitoring of continued response to specific drug.
Our pharma-partner team has your needs in mind, offering services and collaborations in pre-clinical, clinical, and companion diagnostic (CDx) initiatives. The team includes clinical, regulatory, and technology expertise.
We focus on a complete assay system solution from laboratory workflow and assay robustness to assay distribution and support. Optimizing assay turn-around-time (TAT) and hands-on-time (HOT) as well as global registration and distribution are in our team’s DNA.